Xtant Medical Holdings Inc (XTNT) is Initiated by Aegis Capital to Buy, Price Target at $3.50

Xtant Medical Holdings Inc (XTNT) was Initiated by Aegis Capital to “Buy” and the brokerage firm has set the Price Target at $3.50. Aegis Capital advised their investors in a research report released on Nov 30, 2016.

In a different news, on May 10, 2016, Daniel S Goldberger (CEO) purchased 5,000 shares at $2.34 per share price. According to the SEC, on Dec 3, 2015, Kent L Swanson (director) purchased 3,300 shares at $2.83 per share price.

Bacterin International Holdings Inc. is engaged in developing manufacturing and marketing biologics products to domestic and international markets. The Company’s bone graft products are used in a range of applications including enhancing fusion in spine surgery relief of back pain through facet joint stabilization promotion of bone growth in foot and ankle surgery promotion of skull healing following neurosurgery and subchondral bone repair in knee and other joint surgeries. The Company’s acellular dermis scaffolds are utilized in wound care and plastic and reconstructive procedures. The Company also develops custom surgical instruments for use with its allografts. The Company’s products include OsteoSponge OsteoSponge SC OsteoSelect DBM putty OsteoWrap OsteoLock BacFast HD OsteoSTX hMatrix and its line of 3Demin products as well as other allograft products.

Xtant Medical Holdings Inc

Leave a Reply

Xtant Medical Holdings Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Xtant Medical Holdings Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.